Literature DB >> 26863094

Osteogenesis imperfecta: Ultrastructural and histological findings on examination of skin revealing novel insights into genotype-phenotype correlation.

M Balasubramanian1, G J Sobey1,2, B E Wagner3, L C Peres4, J Bowen1,2, J Bexon2, M K Javaid5, P Arundel6, N J Bishop6.   

Abstract

Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. Over 90% of patients with OI have a mutation in COL1A1/COL1A2, which shows an autosomal dominant pattern of inheritance. In-depth phenotyping and in particular, studies involving manifestations in the skin connective tissue have not previously been undertaken in OI. The aims of the study were to perform histological and ultrastructural examination of skin biopsies in a cohort of patients with OI; to identify common and distinguishing features in order to inform genotype-phenotype correlation; and to identify common and distinguishing features between the different subtypes of OI. As part of the RUDY (Rare Diseases in Bone, Joints and/or Blood Vessels) study, in collaboration with the NIHR Rare Diseases Translational Research Collaboration, we undertook a national study of skin biopsies in patients with OI. We studied the manifestations in the skin connective tissue and undertook in-depth clinical and molecular phenotyping of 16 patients with OI. We recruited 16 patients: analyses have shown that in type 1 collagen mutation positive patients (COL1A1/ COL1A2) (n-4/16) consistent findings included: variable collagen fibril diameter (CFD) and presence of collagen flowers. Histological examination in these patients showed an increase in elastic fibers that are frequently fragmented and clumped. These observations provide evidence that collagen flowers and CFD variability are consistent features in OI due to type 1 collagen defects and reinforce the need for accurate phenotyping in conjunction with genomic analyses.

Entities:  

Keywords:  COL1A1/COL1A2; collagen fibril diameter; collagen flowers; elastic fibers; electron microscopy; osteogenesis imperfecta; type 1 collagen

Mesh:

Substances:

Year:  2016        PMID: 26863094     DOI: 10.3109/01913123.2016.1140253

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  5 in total

1.  Severe osteogenesis imperfecta caused by CREB3L1 mutation in a cat.

Authors:  Masamine Takanosu; Yumiko Kagawa
Journal:  J Vet Diagn Invest       Date:  2022-02-15       Impact factor: 1.569

2.  Loss of Type I Collagen Telopeptide Lysyl Hydroxylation Causes Musculoskeletal Abnormalities in a Zebrafish Model of Bruck Syndrome.

Authors:  Charlotte Gistelinck; Paul Eckhard Witten; Ann Huysseune; Sofie Symoens; Fransiska Malfait; Daria Larionova; Pascal Simoens; Manuel Dierick; Luc Van Hoorebeke; Anne De Paepe; Ronald Y Kwon; MaryAnn Weis; David R Eyre; Andy Willaert; Paul J Coucke
Journal:  J Bone Miner Res       Date:  2016-10-24       Impact factor: 6.741

3.  Cytoskeleton and nuclear lamina affection in recessive osteogenesis imperfecta: A functional proteomics perspective.

Authors:  Assunta Gagliardi; Roberta Besio; Chiara Carnemolla; Claudia Landi; Alessandro Armini; Mona Aglan; Ghada Otaify; Samia A Temtamy; Antonella Forlino; Luca Bini; Laura Bianchi
Journal:  J Proteomics       Date:  2017-08-09       Impact factor: 4.044

4.  4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion.

Authors:  Roberta Besio; Giusy Iula; Nadia Garibaldi; Lina Cipolla; Simone Sabbioneda; Marco Biggiogera; Joan C Marini; Antonio Rossi; Antonella Forlino
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-02-10       Impact factor: 5.187

5.  Compound phenotype of osteogenesis imperfecta and Ehlers-Danlos syndrome caused by combined mutations in COL1A1 and COL5A1.

Authors:  Zejia Lin; Jican Zeng; Xinjia Wang
Journal:  Biosci Rep       Date:  2019-07-25       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.